ArticleJournal of the Chinese Medical Association : JCMA2025
Digital polymerase chain reaction quantification of hematopoietic chimerism by insertion/deletion: A personalized selection for different chimerism status.
Article in Journal of the Chinese Medical Association : JCMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer patients: First-line therapy.Journal of the Chinese Medical Association : JCMA · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical decision-making after allogeneic stem cell transplantation (HSCT) is partially based on hematopoietic chimerism analysis. Short tandem repeat (STR), the current gold standard for quantitative chimerism analysis, has limited sensitivity. Digital polymerase chain reaction (dPCR) offers precise quantification and high reproducibility with excellent sensitivity (usually ≤0.1%) across a wide measurement range. However, the reported dPCR-based chimerism detection methods were developed in non-Chinese cohorts and may not be directly applicable to the Chinese population.
methodsTo improve sensitivity and accuracy, we first screened out 14 insertions/deletions (indel) loci with high individual recognition rates in Asian populations based on literature and NCBI data. Then, we established a dPCR detection system for routine chimerism assessment ("dPCR-chimerism system") in Chinese transplant recipients. We compared the concordance between STR and dPCR in patient samples.
resultsThe newly developed dPCR-chimerism system covers all 12 pairs of autosomes, achieves a sensitivity of 0.01%, and demonstrates excellent linearity from 0.016% to 50%. For dual-donor samples, there was a strong correlation between STR and dPCR-chimerism detection values ( R2 = 0.9974). The R2 of the dPCR results was higher than STR when the theoretical chimerism rate of the single recipient was ≤5%. Clinical validation in 44 HSCT patients showed strong overall concordance between STR and dPCR (mean difference: 0.68%), although discrepancies were noted in some cases.
conclusionOur newly developed system demonstrates excellent repeatability and sensitivity, particularly in detecting. It is expected to show good applicability in Chinese transplant patients. Selecting between dPCR and STR testing based on individual chimerism status can facilitate sensitive and accurate analysis, enable timely therapeutic intervention, and support effective relapse monitoring in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.